Which statement best describes COPD pharmacologic treatment with bronchodilators?

• A. Systemic antibiotics
• B. Diuretics
• C. Antitussives
• D. Aerosolized bronchodilators (SABA, LABA, anticholinergic, LAMA)

Answer: (D)

The main concept is that COPD treatment centers on inhaled bronchodilators to relieve airway obstruction and improve airflow. In COPD, airway narrowing comes from smooth muscle constriction and chronic inflammation, so relaxing the airway muscles and reducing resistance helps reduce dyspnea and improve exercise tolerance. The best description is aerosolized bronchodilators, including short-acting beta-agonists for rapid relief, long-acting beta-agonists for sustained control, and anticholinergic (muscarinic) agents for ongoing bronchodilation. Delivering these drugs by inhalation targets the lungs directly, providing quick local effect with fewer systemic side effects, and they can be given via inhalers or nebulizers. Systemic antibiotics are used for infections, not to widen airways. Diuretics don’t affect bronchial tone in COPD. Antitussives address coughing but don’t improve airway caliber. So, the statement that emphasizes aerosolized bronchodilators across SABA, LABA, and anticholinergic (LAMA) categories best describes the bronchodilator-focused pharmacologic approach in COPD.